Altimmune Inc.
(ALT)
undefined
undefined%
At close: undefined
8.99
0.06%
After-hours Dec 13, 2024, 06:44 PM EST
Company Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.
The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis.
It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.
The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015.
Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Altimmune Inc.
| Country | United States |
| IPO Date | May 26, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Dr. Vipin K. Garg Ph.D. |
Contact Details
Address: 910 Clopper Road Gaithersburg, Maryland United States | |
| Website | https://altimmune.com |
Stock Details
| Ticker Symbol | ALT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326190 |
| CUSIP Number | 02155H200 |
| ISIN Number | US02155H2004 |
| Employer ID | 20-2726770 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vipin K. Garg Ph.D. | President, Chief Executive Officer & Director |
| Bertrand Georges Ph.D. | Chief Technology Officer |
| Gregory L. Weaver CPA, M.B.A. | Chief Financial Officer |
| Andrew Shutterly M.S. | Principal Financial & Accounting Officer and Corporate Controller |
| Dr. M. Scot Roberts Ph.D. | Chief Scientific Officer |
| Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS | Chief Medical Officer |
| Raymond M. Jordt M.B.A. | Chief Business Officer |
| Tony Blandin B.S. | Vice President of Quality & Compliance Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 11, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 4 | Filing |
| Nov 12, 2024 | 3 | Filing |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 17, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 16, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 30, 2024 | 4 | Filing |
| Sep 30, 2024 | 4 | Filing |